Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191


Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.

Grady D, Cauley JA, Geiger MJ, Kornitzer M, Mosca L, Collins P, Wenger NK, Song J, Mershon J, Barrett-Connor E; Raloxifene Use for The Heart Trial Investigators.

J Natl Cancer Inst. 2008 Jun 18;100(12):854-61. doi: 10.1093/jnci/djn153. Epub 2008 Jun 10.


Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR; CORE Investigators.

J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61.


Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.

Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.

Curr Med Res Opin. 2008 Mar;24(3):807-13. doi: 10.1185/030079908X273282. Epub 2008 Feb 5.


Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.

Lippman ME, Cummings SR, Disch DP, Mershon JL, Dowsett SA, Cauley JA, Martino S.

Clin Cancer Res. 2006 Sep 1;12(17):5242-7.


Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.

Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG.

Breast Cancer Res Treat. 2001 Jan;65(2):125-34. Erratum in: Breast Cancer Res Treat 2001 May;67(2):191.


Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.

Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK; Raloxifene Use for The Heart (RUTH) Trial Investigators.

N Engl J Med. 2006 Jul 13;355(2):125-37.


Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.

Johnell O, Cauley JA, Kulkarni PM, Wong M, Stock JL.

J Fam Pract. 2004 Oct;53(10):789-96. Erratum in: J Fam Pract. 2005 Mar;54(3):276.


Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.

Lippman ME, Krueger KA, Eckert S, Sashegyi A, Walls EL, Jamal S, Cauley JA, Cummings SR.

J Clin Oncol. 2001 Jun 15;19(12):3111-6. Erratum in: J Clin Oncol 2002 Mar 1;20(5):1430.


Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR; Continuing Outcomes Relevant to Evista (CORE) Investigators.

J Bone Miner Res. 2005 Sep;20(9):1514-24. Epub 2005 May 16.


From adjuvant therapy to breast cancer prevention: BCPT and STAR.

Dunn BK, Ford LG.

Breast J. 2001 May-Jun;7(3):144-57. Review.


The rise of raloxifene and the fall of invasive breast cancer.

Jordan VC.

J Natl Cancer Inst. 2008 Jun 18;100(12):831-3. doi: 10.1093/jnci/djn177. Epub 2008 Jun 10. No abstract available.


Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.

Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ.

J Bone Miner Res. 2004 Aug;19(8):1270-5. Epub 2004 Apr 12.


Raloxifene: a review of its use in postmenopausal osteoporosis.

Clemett D, Spencer CM.

Drugs. 2000 Aug;60(2):379-411. Review.


Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP).

JAMA. 2006 Jun 21;295(23):2727-41. Epub 2006 Jun 5. Erratum in: JAMA. 2006 Dec 27;296(24):2926. JAMA. 2007 Sep 5;298(9):973.


Design and methods of the Raloxifene Use for The Heart (RUTH) study.

Mosca L, Barrett-Connor E, Wenger NK, Collins P, Grady D, Kornitzer M, Moscarelli E, Paul S, Wright TJ, Helterbrand JD, Anderson PW.

Am J Cardiol. 2001 Aug 15;88(4):392-5.


Raloxifene: a review of its use in the prevention of invasive breast cancer.

Moen MD, Keating GM.

Drugs. 2008;68(14):2059-83. Review.


Recommendations for raloxifene use in daily clinical practice in the Swiss setting.

Lippuner K, Buchard PA, De Geyter C, Imthurn B, Lamy O, Litschgi M, Luzuy F, Schiessl K, Stute P, Birkhäuser M.

Eur Spine J. 2012 Dec;21(12):2407-17. doi: 10.1007/s00586-012-2404-y. Epub 2012 Jun 28. Review.


Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial.

Ensrud KE, Stock JL, Barrett-Connor E, Grady D, Mosca L, Khaw KT, Zhao Q, Agnusdei D, Cauley JA.

J Bone Miner Res. 2008 Jan;23(1):112-20.

Items per page

Supplemental Content

Write to the Help Desk